REG - OptiBiotix Health - Exercise of Warrants

OptiBiotix HealthAnnouncement

27/01/2022 10:40

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220127:nRSa8611Za&default-theme=true

RNS Number : 8611Z  OptiBiotix Health PLC  27 January 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Exercise of Warrants

 

OptiBiotix Health plc (AIM:
OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces that it has received
notification to exercise warrants over 125,000 new ordinary shares of 2p each
in the capital of the Company ("Ordinary Shares"). The exercise price of the
warrants was 8p per share. The current issued share capital for Optibiotix
Health plc is 87,940,601 ordinary shares of 2p.

 

Application will be made for the 125,000 new Ordinary Shares to be admitted to
trading on AIM, which is expected to occur at 8.00 a.m. on or around 2
February 2022. The new Ordinary Shares will rank pari passu with the
existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue
of shares detailed above the enlarged issued share capital of the Company will
comprise 88,065,601 ordinary shares of 2p each. The Company does not hold any
ordinary shares in treasury. The above figure may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company, under the Disclosure and Transparency Rules.

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                      www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                       Tel: 020 7213 0880

 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                             Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                            Mob: 07876 741 001
 Anna Dunphy

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFZGZMGNKGZZM